SMO and brain cancer: Despite showing impressive therapeutic activity in nonmelanoma skin cancer, brain cancer, and AML, frequent and rapid resistance development urgently calls for the next generation of HH pathway inhibitors able to block both wild-type and mutant SMO proteins.